home / stock / blco / blco news


BLCO News and Press, Bausch + Lomb Corporation

Stock Information

Company Name: Bausch + Lomb Corporation
Stock Symbol: BLCO
Market: NYSE
Website: bausch.com

Menu

BLCO BLCO Quote BLCO Short BLCO News BLCO Articles BLCO Message Board
Get BLCO Alerts

News, Short Squeeze, Breakout and More Instantly...

BLCO - Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position

2026-03-12 13:46:22 ET On February 17, 2026, Caspian Capital disclosed a purchase of 1,349,043 shares of Bausch + Lomb Corporation (NYSE:BLCO) , an estimated $21.39 million trade based on quarterly average pricing. According to its SEC filing dated February 17, 2026, Caspian...

BLCO - Bausch + Lomb Launches R&D "Teach-in" Webinar Series

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D “Teach-in” webinar series that will provide deeper insights on the company’s differentiated pro...

BLCO - Most and least shorted mid-to mega-cap healthcare stocks in February

2026-03-04 09:35:44 ET Health Care ETFs: ( XLV ), ( VHT ), ( IHI ), ( IXJ ), ( IYH ), ( FHLC ), ( XPH ), ( PPH ...

BLCO - FedEx, EssilorLuxottica sued by customers for tariff refunds

2026-02-28 14:16:27 ET More on FedEx, EssilorLuxottica ADR FedEx Corporation (FDX) Analyst/Investor Day Transcript EssilorLuxottica: Turning Positive On Market-Share Gain (Rating Upgrade) FedEx Investor Day: Strong Run, Weak Catalyst (Rating Downgrade) FedEx ...

BLCO - Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

Global review highlights increasing prevalence of noninfectious ocular redness due to digital eye strain, dry eye disease, allergies and environmental exposures LUMIFY redness reliever eye drops (brimonidine tartrate 0.025%) are highlighted as a differentiated OTC option due to its highly sel...

BLCO - Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats

2026-02-19 14:54:45 ET Investment Overview Bausch + Lomb Corporation ( BLCO ), a leading global eye health specialist and marketer and seller of ~400 products in total (source: Q3 2025 10-Q filing ), announced its Q4 and full-year earnings on February 18th.... Read...

BLCO - How Bausch Health's Turnaround Progressed In Q4 2025

2026-02-19 10:07:31 ET Last October 2025, Bausch Health Companies Inc. ( BHC ) jumped by 1% after it posted third quarter results . This time, the fourth-quarter bottom line missed expectations. Both its revenue for Q4 and revenue guidance for 2026 exceeded consensus. However, t...

BLCO - Bausch + Lomb outlines 2026 revenue target of $5.475B with margin expansion driven by dry eye growth

2026-02-18 12:56:09 ET More on Bausch + Lomb Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript Bausch + Lomb Corporation 2025 Q4 - Results - Earnings Call Presentation Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Con...

BLCO - Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript

2026-02-18 12:55:09 ET Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call February 18, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript

BLCO - Bausch + Lomb reports mixed results; initiates FY26outlook

2026-02-18 07:01:55 ET More on Bausch + Lomb Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Bausch + Lomb: I ...

Next 10